This week in drug discovery (3-7 February)
News round-up for 3-7 February by DDW Senior Digital Content Editor Diana Spencer.
Following World Cancer Day on 4 February, the news round-up this week focuses on new approaches to the treatment of cancer, including radiopharmaceuticals, programmable cell depletion and preventative vaccines.
The top stories:
FDA Orphan Drug Designation for CD5 CAR-T cell therapy
The US Food and Drug Administration (FDA) has granted orphan drug designation to MB-105, March Biosciences’ CD5-targeted CAR-T cell therapy for the treatment of relapsed/refractory CD5-positive T-cell lymphoma (TCL).
Study reveals role of the secretome in cancer drug resistance
A new study has shown that non-cancerous cells positioned close to tumours can affect how cancer responds to treatment.
€8m financing to pioneer RNA-guided, programmable cell depletion
Akribion Therapeutics has exited stealth mode and completed a seed financing round, raising €8 million to accelerate the development of novel therapeutics.
Oxford and GSK launch £50m cancer vaccines programme
GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines.
Radiopharmaceutical cancer therapy granted orphan drug status
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ariceum Therapeutics’ 225Ac-SSO110 (satoreotide) for the treatment of patients with small cell lung cancer (SCLC).
